INVU
Investview, Inc.0.0300
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
55.59MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
Investview's Q2 revenue dipped 24% year-over-year to $10.0M, driven by a 35% drop in membership fees to $7.8M amid post-pandemic spending shifts, while mining revenue fell 23% to $0.8M due to Bitcoin halving and network difficulty; health and wellness sales added $1.3M from the October 2024 Renu Labs acquisition. Operating costs trimmed 21% to $10.0M, yielding a slim $17K operating loss versus $0.5M profit last year, with net income swinging to $0.4M profit from $0.5M on unrealized digital asset gains under new fair value accounting. Cash holds steady at $16.2M after $3.7M operating outflow, supporting $2.9M total debt including related-party notes at 20-38.5% rates maturing 2030; free cash flow not disclosed in the 10-Q. Foreign sales comprise 67% of revenue. Regulatory scrutiny in Poland over direct selling model poses ongoing compliance risks.
10-Q
Q1 FY2025 results
Investview's Q1 FY2025 revenue fell 36% year-over-year to $10.0M, driven by a 33% drop in membership fees to $8.8M amid post-pandemic shifts and a 67% plunge in mining income to $0.9M following the Bitcoin halving, though health and wellness sales added $0.4M from the October 2024 Renu Labs acquisition for $1.8M, recognizing $0.9M goodwill and $0.04M indefinite-lived domain names. Operating loss widened to $0.4M from a $1.9M profit, with net loss of $0.7M versus $1.7M income, the gap mainly from $0.2M unrealized digital asset losses under new fair value rules and $0.3M related-party interest. Cash dipped to $17.5M, supporting $14.2M working capital against $2.8M related-party debt at 20-38.5% rates due 2030. Regulatory scrutiny in Poland over iGenius' direct-selling model poses a key risk.
8-K
Share repurchase deal terminated
Investview terminated its October 2024 agreement to repurchase 121 million common shares from three non-affiliate sellers after they failed to deliver by the extended May 1, 2025 deadline. The deal aimed to cut outstanding shares and settle a 2017 issuance dispute. Termination preserves the company's capitalization. It reserves all rights against future share transfers.
10-K
FY2024 results
Investview's FY2024 revenue fell 23% y/y to $52.4M, driven by a 16% drop in iGenius membership fees to $47.1M amid post-pandemic spending shifts and a 54% plunge in SAFETek mining output to 85.92 Bitcoin, hit by the April halving, 29% network difficulty spike, and 60% power curtailments from low hydro levels—yet Q4 saw operational tweaks like retiring inefficient miners and deploying high-efficiency ASICs to cut hash costs and stem losses. New acquisitions of Opencash in March and Renu Labs in October added negligible revenue but signal diversification into brokerage and wellness, with $110K from health products. Cash swelled to $22.5M after $8.3M operating inflow, funding $3.4M share repurchases and $1.1M Renu buy; related-party debt stands at $2.7M with amended lower rates ahead. No 2025 guidance disclosed, but Bitcoin power woes persist as a key risk to quarterly momentum.
BULL
Webull Corporation
8.56-0.06
DFIN
Donnelley Financial Solutions,
45.40+0.84
DV
DoubleVerify Holdings, Inc.
11.17+0.34
FTFT
Future FinTech Group Inc.
0.97-0.07
FYNN
Fyntechnical Innovations, Inc.
0.00+0.00
INTU
Intuit Inc.
669.35+14.76
INUV
Inuvo, Inc.
2.69-0.06
RDVT
Red Violet, Inc.
54.31+0.62
VMEO
Vimeo, Inc.
7.85+0.00
WONDF
Wonderfi Technologies Inc.
0.21+0.00